Emerging research suggest Retatrutide , a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , could represent a promising advancement for body management . Preliminary clinical investigations have indicated impressive reductions in visceral tissue, conceivably exceeding other obesity treatments. Nevertheless , ad